Advantages and Disadvantages of Intensive Split-Dose Radiation Therapy

2015 ◽  
pp. 163-172 ◽  
Author(s):  
S. H. Levitt ◽  
C. R. Bogardus
Keyword(s):  
Radiation Therapy ◽  
Split Dose ◽  
Advantages And Disadvantages ◽  
Dose Radiation

Plasma cell infiltration of the upper aerodigestive tract treated with radiation therapy

2001 ◽  
Vol 115 (11) ◽  
pp. 928-930 ◽  
Author(s):  
Gerald Fogarty ◽  
Hugh Turner ◽  
June Corry
Keyword(s):  
Radiation Therapy ◽  
Plasma Cell ◽  
Low Dose ◽  
Symptomatic Improvement ◽  
Upper Aerodigestive Tract ◽  
Low Dose Radiation ◽  
Base Of Tongue ◽  
First Case ◽  
Mucosal Lining ◽  
Dose Radiation

A case of chronic, fluctuating plasma cell gingivostomatitis that progressed despite chemotherapy and surgery is reported. This is the first case reported of treatment with radiation therapy, and one of the few cases reported where the infiltrate has reached the larynx. After receiving low dose radiation therapy, via a conformal technique encompassing the respiratory mucosal lining from the base of tongue to carina, there has been symptomatic improvement.

scholarly journals 4DCT radiotherapy for NSCLC: a review of planning methods

2014 ◽  
Vol 14 (1) ◽  
pp. 70-79 ◽  
Author(s):  
A. Hutchinson ◽  
P. Bridge
Keyword(s):  
Computed Tomography ◽  
Radiation Therapy ◽  
Early Stage ◽  
Organs At Risk ◽  
Patient Comfort ◽  
Or Education ◽  
Optimal Method ◽  
Early Stage Disease ◽  
Advantages And Disadvantages ◽  
Stage Disease

AbstractPurposeTo establish whether the use of a passive or active technique of planning target volume (PTV) definition and treatment methods for non-small cell lung cancer (NSCLC) deliver the most effective results. This literature review assesses the advantages and disadvantages in recent studies of each, while assessing the validity of the two approaches for planning and treatment.MethodsA systematic review of literature focusing on the planning and treatment of radiation therapy to NSCLC tumours. Different approaches which have been published in recent articles are subjected to critical appraisal in order to determine their relative efficacy.ResultsFree-breathing (FB) is the optimal method to perform planning scans for patients and departments, as it involves no significant increase in cost, workload or education. Maximum intensity projection (MIP) is the fastest form of delineation, however it is noted to be less accurate than the ten-phase overlap approach for computed tomography (CT). Although gating has proven to reduce margins and facilitate sparing of organs at risk, treatment times can be longer and planning time can be as much as 15 times higher for intensity modulated radiation therapy (IMRT). This raises issues with patient comfort and stabilisation, impacting on the chance of geometric miss. Stereotactic treatments can take up to 3 hours to treat, along with increases in planning and treatment, as well as the additional hardware, software and training required.ConclusionFour-dimensional computed tomography (4DCT) is superior to 3DCT, with the passive FB approach for PTV delineation and treatment optimal. Departments should use a combination of MIP with visual confirmation ensuring coverage for stage 1 disease. Stages 2–3 should be delineated using ten-phases overlaid. Stereotactic and gated treatments for early stage disease should be used accordingly; FB-IMRT is optimal for latter stage disease.

scholarly journals Low-Dose Radiation Therapy for COVID-19 Pneumonia: review

2020 ◽  
pp. 30-34
Author(s):  
N. Kolotilov
Keyword(s):  
Radiation Therapy ◽  
Low Dose ◽  
Ore Deposits ◽  
Molecular Targeting ◽  
Positive Experience ◽  
Low Dose Radiation ◽  
Coronavirus Infection ◽  
Positive Results ◽  
Dose Radiation ◽  
Radiolabeled Antibodies

The use of low-dose radiation therapy (LDRT) in patients with pneumonia from 1905 to 1943 provided positive results in 83.08 % of cases. Interest in LDRT is supported by researchers of radiation hormesis in the 21st century. Attention is drawn to the dynamics of coronavirus infection in the regions of Ukraine and the Kirovograd region with a minimum incidence. It is known that 95 % of uranium ore deposits in Ukraine are concentrated in the Kirovograd region. The positive experience of LDRT in Iran, India, USA, Spain for the treatment of patients with COVID-19 is described. LDRT (<100 cGy) is known to be anti-inflammatory, and therefore pulmonary LDRT has the potential to reduce the severity of pneumonia and reduce mortality. LDRT deserves a clinical study. A new direction in radiation therapy – Auger therapy based on radiolabeled antibodies – is planned to be used as a molecular targeting radiotherapy agent directly to the SARS-CoV-2.

scholarly journals Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)

2021 ◽  
pp. JCO.20.03128
Author(s):  
Sue S. Yom ◽  
Pedro Torres-Saavedra ◽  
Jimmy J. Caudell ◽  
John N. Waldron ◽  
Maura L. Gillison ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Radiation Treatment ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Oropharyngeal Carcinoma ◽  
Reduced Dose ◽  
Phase Iii Study ◽  
Grade 3 ◽  
Dose Radiation

PURPOSE Reducing radiation treatment dose could improve the quality of life (QOL) of patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC). Whether reduced-dose radiation produces disease control and QOL equivalent to standard chemoradiation is not proven. PATIENTS AND METHODS In this randomized, phase II trial, patients with p16-positive, T1-T2 N1-N2b M0, or T3 N0-N2b M0 OPSCC (7th edition staging) with ≤ 10 pack-years of smoking received 60 Gy of intensity-modulated radiation therapy (IMRT) over 6 weeks with concurrent weekly cisplatin (C) or 60 Gy IMRT over 5 weeks. To be considered for a phase III study, an arm had to achieve a 2-year progression-free survival (PFS) rate superior to a historical control rate of 85% and a 1-year mean composite score ≥ 60 on the MD Anderson Dysphagia Inventory (MDADI). RESULTS Three hundred six patients were randomly assigned and eligible. Two-year PFS for IMRT + C was 90.5% rejecting the null hypothesis of 2-year PFS ≤ 85% ( P = .04). For IMRT, 2-year PFS was 87.6% ( P = .23). One-year MDADI mean scores were 85.30 and 81.76 for IMRT + C and IMRT, respectively. Two-year overall survival rates were 96.7% for IMRT + C and 97.3% for IMRT. Acute adverse events (AEs) were defined as those occurring within 180 days from the end of treatment. There were more grade 3-4 acute AEs for IMRT + C (79.6% v 52.4%; P < .001). Rates of grade 3-4 late AEs were 21.3% and 18.1% ( P = .56). CONCLUSION The IMRT + C arm met both prespecified end points justifying advancement to a phase III study. Higher rates of grade ≥ 3 acute AEs were reported in the IMRT + C arm.

Sign in / Sign up

Export Citation Format

Share Document